Bobby的个人博客分享 http://blog.sciencenet.cn/u/Bobby

博文

匹兹堡大学新型冠状病毒(SARS-CoV-2)疫苗来取得进展(外一)

已有 14856 次阅读 2020-4-3 22:57 |个人分类:科学感想|系统分类:论文交流

匹兹堡大学新型冠状病毒(SARS-CoV-2)疫苗来取得进展


COVID-19 vaccine candidate shows promise, research shows

https://www.sciencedaily.com/releases/2020/04/200402144508.htm


Journal Reference:

  1. Eun Kima, Geza Erdosb, Shaohua Huanga, Thomas W. Kennistona, Stephen C. Balmertb,Cara Donahue Careyb, V. Stalin Raje,1, Michael W. Epperlyc, William B. Klimstrad,Bart L. Haagmanse, Emrullah Korkmazb,f, Louis D. Falo Jr.b,f,g,h,*, Andrea Gambotto. Microneedle array delivered recombinant coronavirus vaccines:Immunogenicity and rapid translational development. EBioMedicine, 2020 DOI: 10.1016/j.ebiom.2020.102743

==========================


一个国际研究小组发现了一种试验药物,可以有效地阻断SARS-CoV-2来感染宿主的细胞


“我们的新研究提供了非常需要的直接证据,证明一种即将在欧洲生物技术公司Apeiron Biologics进行临床试验的药物——APN01(人类重组可溶性血管紧张素转换酶2——(human recombinant soluble angiotensin-converting enzyme 2,hrsACE2)——作为COVID-19的抗病毒治疗是有用的,”Art Slutsky博士说


 Trial drug can significantly block early stages of COVID-19 in engineered human tissues

https://www.sciencedaily.com/releases/2020/04/200402144526.htm


Journal Reference:

  1. Vanessa Monteil, Hyesoo Kwon, Patricia Prado, Astrid Hagelkrüys, Reiner A. Wimmer, Martin Stahl, Alexandra Leopoldi, Elena Garreta, Carmen Hurtado Del Pozo, Felipe Prosper, J.p. Romero, Gerald Wirnsberger, Haibo Zhang, Arthur S. Slutsky, Ryan Conder, Nuria Montserrat, Ali Mirazimi, Josef M. Penninger. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Submitted to Cell, 2020 DOI: 10.1016/j.cell.2020.04.004

 



https://blog.sciencenet.cn/blog-39731-1226744.html

上一篇:基因说了算
下一篇:肥胖者大腿粗与较低的血压和降低心脏病风险有关
收藏 IP: 150.255.15.*| 热度|

1 杨正瓴

该博文允许注册用户评论 请点击登录 评论 (0 个评论)

数据加载中...
扫一扫,分享此博文

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2024-9-19 14:36

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部